Renovascular Hypertension
文献摘要
Renovascular hypertension (RVH) is defined as systemic hypertension resulting from compromised blood flow to one or both kidneys, most commonly due to renal artery stenosis. RVH represents one of the most prevalent and clinically significant forms of secondary hypertension, accounting for approximately 1% to 5% of all hypertensive patients in the general population, but up to 20% to 40% of patients presenting with resistant or malignant hypertension. RVH encompasses a spectrum of clinical syndromes, ranging from asymptomatic renovascular disease to overt renal failure (ischemic nephropathy), flash pulmonary edema, and accelerated cardiovascular morbidity. The foundational understanding of RVH traces back to the seminal experiments of Goldblatt in 1934, who demonstrated that clamping the renal artery in dogs produced sustained systemic hypertension, thereby establishing the mechanistic link between renal ischemia and blood pressure elevation. Since then, our understanding has evolved considerably, with contemporary evidence from landmark randomized controlled trials—including ASTRAL (Angioplasty and Stenting for Renal Artery Lesions), CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions), and STAR (Stent Placement in Patients With Atherosclerotic Renal Artery Stenosis and Impaired Renal Function)—fundamentally reshaping the therapeutic paradigm. This review provides a comprehensive, evidence-based synthesis of the current state of knowledge regarding renovascular hypertension, incorporating the most recent Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Blood Pressure in chronic kidney disease (CKD) Guideline, the KDIGO 2024 CKD Evaluation and Management Guideline, the 2022 KDIGO Controversies Conference on Atherosclerotic Renovascular Disease, the 2023 European Society of Hypertension (ESH) and 2024 European Society of Cardiology (ESC) hypertension guidelines, the 2023 European Renal Best Practice (ERBP) clinical practice document, the 2022 American Heart Association (AHA) Scientific Statement on Revascularization for Renovascular Disease, the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography & Interventions/Society of Interventional Radiology/Society for Vascular Medicine (ACC/AHA/SCAI/SIR/SVM) 2018 Appropriate Use Criteria for Peripheral Artery Intervention, the SCAI Expert Consensus for renal artery stenting, the brand-new European Society for Vascular Surgery (ESVS) 2025 Clinical Practice Guidelines on Mesenteric and Renal Arteries, and emerging therapeutic modalities including renal denervation.